InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.190
+0.040 (3.48%)
Mar 14, 2025, 4:00 PM EDT - Market closed
InflaRx Revenue
InflaRx had revenue of 123.82K EUR in the quarter ending September 30, 2024, with 103.64% growth. This brings the company's revenue in the last twelve months to 168.50K, up 177.12% year-over-year. In the year 2023, InflaRx had annual revenue of 63.09K.
Revenue (ttm)
168.50K EUR
Revenue Growth
+177.12%
P/S Ratio
372.86
Revenue / Employee
2,709 EUR
Employees
62
Market Cap
70.07M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IFRX News
- 8 days ago - InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 14 days ago - InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 18 days ago - InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences - GlobeNewsWire
- 24 days ago - InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 7 weeks ago - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) - GlobeNewsWire